[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Osteoarthritis Therapeutics Market by Anatomy (Knee, Hip), Drug Type (NSAIDs, Corticosteroids), Route of Administration (Parenteral, Topical), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecast to 2024

October 2019 | 148 pages | ID: O288174C34A7EN
MarketsandMarkets

US$ 5,650.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
“The osteoarthritis therapeutics market is projected to register a CAGR of 8.1% during the forecast period.”

The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8 billion in 2019, at a CAGR of 8.1%. Growth in this industry is driven by the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. On the other hand, the availability of alternative non-drug pain management therapies is a major market challenge.

“Knee osteoarthritis segment to witness the highest growth during the forecast period.”

Based on anatomy, the osteoarthritis therapeutics market is segmented into knee, hip, hand, and small-joint. The knee osteoarthritis segment is projected to grow at the highest CAGR during the forecast period. A large number of patients suffering from knee osteoarthritis is the major factor supporting the growth of this segment.

“Viscosupplementation agents segment to register the highest growth in the osteoarthritis therapeutics market during the forecast period.”

Based on drug type, the osteoarthritis therapeutics market is segmented into viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids. The analgesics segment is sub-segmented into duloxetine and acetaminophen, while the NSAIDs segment is sub-segmented into naproxen, aspirin, diclofenac, ibuprofen, and other molecules. The viscosupplementation agents segment is projected to witness the highest growth in the osteoarthritis therapeutics market during the forecast period. The rising incidence of knee osteoarthritis is one of the major factors supporting the growth of this segment.

“Asia Pacific is estimated to register the highest CAGR during the forecast period.”

In this report, the osteoarthritis therapeutics market is segmented into four major regional segments, namely, Europe, North America, Asia Pacific, and the Rest of the World (RoW). The market in Asia-Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is driven primarily by the rising incidence and prevalence of osteoarthritis, increasing geriatric and obese populations, and healthcare infrastructure improvements in several APAC countries.

Breakdown of Profiles of Primary Participants:
  • By Company Type: Tier 1: 20%, Tier 2: 45%, and Tier 3: 35%
  • By Designation: C-level: 30%, Director-level: 20%, and Others: 50%
  • By Region: North America: 35%, Europe: 24%, Asia Pacific: 25%, and the Rest of the World: 16%
Key players in the osteoarthritis therapeutics market include Sanofi (France), Horizon Therapeutics (Ireland), Johnson & Johnson (US), GlaxoSmithKline Plc (UK), Bayer AG (Germany), Abbott (US), Pfizer (US), Eli Lilly (US), Anika Therapeutics (US), and Flexion Therapeutics (US).

Research Coverage:

The report analyzes the osteoarthritis therapeutics market by anatomy, drug type, route of administration, distribution channel, purchasing pattern, and region. Apart from comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by market players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.

Key Benefits of Buying the Report:

This report will enable both established firms and new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help these firms garner greater market shares. Firms purchasing the report can use any one, or a combination of the below mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on the product portfolios of the top players in the osteoarthritis therapeutics market
  • Product Development/Innovation: Detailed insights on the product approvals, R&D activities, and product launches in the osteoarthritis therapeutics market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the osteoarthritis therapeutics market
  • Market Development: Detailed information about emerging markets. The report analyzes the market for various osteoarthritis therapeutics across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the osteoarthritis therapeutics market
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
  2.1.1 SECONDARY DATA
    2.1.1.1 Key data from secondary sources
  2.1.2 PRIMARY DATA
    2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
  2.2.1 BOTTOM-UP APPROACH
  2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 OSTEOARTHRITIS THERAPEUTICS MARKET OVERVIEW
4.2 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY ANATOMY (2018)
4.3 GEOGRAPHICAL SNAPSHOT OF THE OSTEOARTHRITIS THERAPEUTICS MARKET

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
  5.2.1 DRIVERS
    5.2.1.1 Rapid growth in the geriatric and obese populations and the associated increase in the prevalence of osteoarthritis
    5.2.1.2 Increasing incidence of sports injuries
  5.2.2 RESTRAINTS
    5.2.2.1 Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment
  5.2.3 OPPORTUNITIES
    5.2.3.1 Emerging markets
    5.2.3.2 Strategic collaborations focused on new product development
  5.2.4 CHALLENGES
    5.2.4.1 Availability of alternative non-drug pain management therapies

6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY

6.1 INTRODUCTION
6.2 KNEE OSTEOARTHRITIS
  6.2.1 RISING OBESE AND GERIATRIC POPULATIONS TO INCREASE THE PREVALENCE OF KNEE OSTEOARTHRITIS
6.3 HIP OSTEOARTHRITIS
  6.3.1 SIMILAR TO KNEE OSTEOARTHRITIS, HIP OSTEOARTHRITIS IS MORE COMMON IN THE GERIATRIC AND OBESE POPULATIONS
6.4 HAND OSTEOARTHRITIS
  6.4.1 RISING PREVALENCE OF SHOULDER OSTEOARTHRITIS TO DRIVE MARKET GROWTH
6.5 SMALL-JOINT OSTEOARTHRITIS
  6.5.1 RISING NUMBER OF ANKLE-RELATED SPORTS INJURIES TO INCREASE THE PREVALENCE OF ANKLE OSTEOARTHRITIS

7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE

7.1 INTRODUCTION
7.2 VISCOSUPPLEMENTATION AGENTS
  7.2.1 VISCOSUPPLEMENTATION AGENTS DOMINATED THE MARKET IN 2018
7.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
  7.3.1 NSAIDS CAN RELIEVE PAIN AND INFLAMMATION WITHOUT THE VARIOUS POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH CORTICOSTEROIDS
    7.3.1.1 Ibuprofen
    7.3.1.2 Diclofenac
    7.3.1.3 Aspirin
    7.3.1.4 Naproxen
    7.3.1.5 Other molecules
7.4 ANALGESICS
  7.4.1 ACETAMINOPHEN
  7.4.2 DULOXETINE
7.5 CORTICOSTEROIDS

8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

8.1 INTRODUCTION
8.2 ORAL ROUTE
8.3 PARENTERAL ROUTE
8.4 TOPICAL ROUTE

9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

9.1 INTRODUCTION
9.2 HOSPITAL PHARMACIES
9.3 ONLINE PHARMACIES
9.4 RETAIL PHARMACIES

10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN

10.1 INTRODUCTION
10.2 PRESCRIPTION DRUGS
  10.2.1 PRESCRIPTION DRUGS TO ACCOUNT FOR A LARGER SHARE OF THE MARKET
10.3 OVER-THE-COUNTER DRUGS
  10.3.1 EASE OF PURCHASE AND ADMINISTRATION RESULTING IN A RISING DEMAND FOR OTC DRUGS

11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION

11.1 INTRODUCTION
11.2 EUROPE
  11.2.1 ITALY
  11.2.2 GERMANY
  11.2.3 SPAIN
  11.2.4 FRANCE
  11.2.5 UK
  11.2.6 REST OF EUROPE
11.3 NORTH AMERICA
  11.3.1 US
  11.3.2 CANADA
11.4 ASIA PACIFIC
  11.4.1 JAPAN
  11.4.2 CHINA
  11.4.3 INDIA
  11.4.4 REST OF ASIA PACIFIC
11.5 REST OF THE WORLD

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW
12.2 MARKET RANKING ANALYSIS, 2018
12.3 COMPETITIVE SCENARIO
  12.3.1 PRODUCT LAUNCHES AND APPROVALS, 2016–2019
  12.3.2 COLLABORATIONS, 2016–2019
  12.3.3 EXPANSIONS, 2016–2019
  12.3.4 ACQUISITIONS, 2016–2019
  12.3.5 OTHER DEVELOPMENTS
12.4 COMPETITIVE LEADERSHIP MAPPING
  12.4.1 VENDOR INCLUSION CRITERIA
  12.4.2 VISIONARY LEADERS
  12.4.3 INNOVATORS
  12.4.4 DYNAMIC DIFFERENTIATORS
  12.4.5 EMERGING COMPANIES

13 COMPANY PROFILES

(Business overview, Products offered, Recent developments, MNM view)*
13.1 SANOFI
13.2 HORIZON THERAPEUTICS PLC
13.3 JOHNSON & JOHNSON
13.4 GLAXOSMITHKLINE PLC
13.5 BAYER AG
13.6 ABBOTT
13.7 PFIZER, INC.
13.8 ELI LILLY
13.9 ANIKA THERAPEUTICS, INC.
13.10 NOVARTIS
13.11 FERRING PHARMACEUTICALS
13.12 BIOVENTUS
13.13 ZIMMER BIOMET HOLDINGS, INC.
13.14 FIDIA FARMACEUTICI S.P.A.
13.15 FLEXION THERAPEUTICS, INC.
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

14 APPENDIX

14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS

LIST OF TABLES

TABLE 1 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 2 KNEE OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 3 HIP OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 4 HAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 5 SMALL-JOINT OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 7 OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 8 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 9 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2017–2024 (USD MILLION)
TABLE 10 OSTEOARTHRITIS THERAPEUTICS MARKET FOR IBUPROFEN, BY REGION, 2017–2024 (USD MILLION)
TABLE 11 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DICLOFENAC, BY REGION, 2017–2024 (USD MILLION)
TABLE 12 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ASPIRIN, BY REGION, 2017–2024 (USD MILLION)
TABLE 13 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NAPROXEN, BY REGION, 2017–2024 (USD MILLION)
TABLE 14 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OTHER MOLECULES, BY REGION, 2017–2024 (USD MILLION)
TABLE 15 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 16 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY REGION, 2017–2024 (USD MILLION)
TABLE 17 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ACETAMINOPHEN, BY REGION, 2017–2024 (USD MILLION)
TABLE 18 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DULOXETINE, BY REGION, 2017–2024 (USD MILLION)
TABLE 19 OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY REGION, 2017–2024 (USD MILLION)
TABLE 20 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 21 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 22 OSTEOARTHRITIS THERAPEUTICS MARKET FOR PARENTERAL ROUTE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 23 OSTEOARTHRITIS THERAPEUTICS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 24 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 25 OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 26 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 27 OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 28 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 29 OSTEOARTHRITIS THERAPEUTICS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2017–2024 (USD MILLION)
TABLE 30 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2017–2024 (USD MILLION)
TABLE 31 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 32 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 33 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 34 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 35 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 36 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 37 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 38 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 39 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 40 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 41 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 42 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 43 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 44 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 45 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 46 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 47 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 48 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 49 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 50 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 51 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 52 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 53 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 54 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 55 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 56 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 57 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 58 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 59 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 60 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 61 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 62 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 63 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 64 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 65 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 66 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 67 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 68 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 69 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 70 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 71 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 72 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 73 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 74 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 75 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 76 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 77 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 78 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 79 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 80 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 81 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 82 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 83 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 84 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 85 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 86 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 87 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 88 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 89 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 90 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 91 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 92 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 93 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 94 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 95 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 96 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 97 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 98 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 99 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 100 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 101 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 102 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 103 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 104 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 105 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 106 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 107 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 108 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 109 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 110 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 111 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 112 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 113 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 114 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 115 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 116 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 117 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 118 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 119 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 120 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 121 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 122 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 123 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 124 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 125 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 126 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 127 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 128 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 129 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 130 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 131 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 132 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 133 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 134 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 135 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 136 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 137 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 138 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 139 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 140 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2024 (USD MILLION)
TABLE 141 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 142 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 143 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 144 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 145 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 146 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)

LIST OF FIGURES

FIGURE 1 OSTEOARTHRITIS THERAPEUTICS MARKET SEGMENTATION
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 OSTEOARTHRITIS THERAPEUTICS MARKET: BOTTOM-UP APPROACH
FIGURE 5 OSTEOARTHRITIS THERAPEUTICS MARKET: TOP-DOWN APPROACH
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2019 VS. 2024 (USD BILLION)
FIGURE 8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2019 VS. 2024 (USD BILLION)
FIGURE 9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019 VS. 2024 (USD BILLION)
FIGURE 10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019 VS. 2024 (USD BILLION)
FIGURE 11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2019 VS. 2024 (USD BILLION)
FIGURE 12 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2019 VS. 2024 (USD BILLION)
FIGURE 13 HIGH AND GROWING PREVALENCE OF OSTEOARTHRITIS IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET
FIGURE 14 KNEE OSTEOARTHRITIS THERAPEUTICS SEGMENT TO DOMINATE THE EUROPEAN MARKET IN 2019
FIGURE 15 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 16 OSTEOARTHRITIS THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17 GERIATRIC POPULATION, BY REGION, 2017 VS. 2050
FIGURE 18 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
FIGURE 19 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
FIGURE 20 KEY DEVELOPMENTS IN THE OSTEOARTHRITIS THERAPEUTICS MARKET FROM JANUARY 2016 TO AUGUST 2019
FIGURE 21 TOP 5 COMPANIES IN THE OSTEOARTHRITIS THERAPEUTICS MARKET
FIGURE 22 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
FIGURE 23 SANOFI: COMPANY SNAPSHOT (2018)
FIGURE 24 HORIZON THERAPEUTICS PLC: COMPANY SNAPSHOT (2018)
FIGURE 25 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2018)
FIGURE 26 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
FIGURE 27 BAYER AG: COMPANY SNAPSHOT (2018)
FIGURE 28 ABBOTT: COMPANY SNAPSHOT (2018)
FIGURE 29 PFIZER, INC.: COMPANY SNAPSHOT (2018)
FIGURE 30 ELI LILLY: COMPANY SNAPSHOT (2018)
FIGURE 31 ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2018)
FIGURE 32 NOVARTIS: COMPANY SNAPSHOT (2018)
FIGURE 33 ZIMMER BIOMET HOLDINGS, INC.: COMPANY SNAPSHOT (2018)
FIGURE 34 FLEXION THERAPEUTICS: COMPANY SNAPSHOT (2018)


More Publications